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SUMMARY 
Recent findings have suggested an important role for variation in levels of 
2,3-diphosphoglycerate and ATP in the regulation of oxygen transport by the human 
erythrocyte, and in making homeostatic adjustments to hypoxia. For this reason, 
the erythrocytic glycolytic mechanisms which control or bring about changes in levels 
of 2,3-diphosphoglycerate and ATP are of vital importance in understanding respira- 
tory homeostasis. Hexokinase is the first step in glycolysis, and available evidence 
suggests that it is an important rate-limiting step in the erythrocyte. In this paper 
we have examined a possible mechanism for feedback control of glycolysis through 
2,3-diphosphoglycerate inhibition of hexokinase activity. We have found that 2,3-di- 
phosphoglycerate does inhibit hexokinase and have shown that the inhibition is 
relieved by increasing concentrations of ATP and Mg 2+. It  is our conclusion that 
inhibition of erythrocyte hexokinase by 2,3-diphosphoglycerate, with modulation by 
ATP and/or Mg 2+, is well suited for feedback control of glycolysis, and hence for the 
control of levels of 2,3-diphosphoglycerate and ATP, which in turn regulate hemo- 
globin function. 
INTRODUCTION 
Recent findings 1-s suggest an important role for variation in levels of 2,3-di- 
phosphoglycerate and ATP in the regulation of oxygen transport by the human 
erythrocyte, and in making homeostatic adjustments to hypoxia. If such is the case 
then the glycolytic mechanisms which control or bring about changes in levels of 
2,3-diphosphoglycerate and ATP are of considerable importance in respiratory home- 
ostatis. Both 2,3-diphosphoglycerate and ATP are synthesized during glycolysis. 
Hexokinase is the first, and possibly a rate-limiting step in erythrocyte glycolysis. 
DISCHE'S early report 9 that 2,3-diphosphoglycerate is capable of inhibiting hexokinase 
suggests a possible feedback inhibition mechanism whereby the levels of 2,3-diphos- 
phoglycerate may be a factor in determining rate of glycolysis, and hence levels of 
2,3-diphosphoglycerate and/or ATP. However, DEVERDIER AND GARBY 1° have not 
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been able to confirm an effect of 2,3-diphosphoglycerate on hexokinase activity. For 
these reasons it is the purpose of this paper to explore iJz vitro the effects of con- 
comitant variation in concentration of three variables, 2,3-diphosphoglycerate, ATP 
and Mg"% upon hexokinase activity of human hemolysates. 
METHODS 
The basic method of measuring hexokinase activity, using a glucose-0-phosphate 
dehydrogenase, 6-phosphoglueonate dehydrogenase coupled system, was similar to 
that previously reported n. 2,3-Diphosphoglycerate was shown to have no effect on 
the coupling enzymes in control experiments. We employed a pH of 7.4 for the assay 
rather than 8.o as in previous studies to make conditions more physiological. Concen- 
trations of 2,3-diphosphoglycerate, ATP, and Mg 2~ (as MgC12) are indicated in each 
experiment. 2,3-Diphosphoglycerate was obtained from the Sigma Chemical Co., 
St. Louis, Mo., as the cyclohexylamine salt. Control experiments demonstrated that 
cyctohexylamine in the molarity employed had m) effect on hexokinase activity. In 
each study of the effect of 2,3-diphosphoglycerate inhibition of hexokinase, a contr(fi 
was performed under exactly the same conditions except that 2,3-diphosphoglycerate 
was olnitted. All results are reported in terms of the percent inhibition, that is the 
percent loss of activity attributed to the presence of 2,3-diphosphoglycerate in the 
experimental cuvette. 
RESULTS 
The inhibition of hexokinase by varying concentrations of 2,3-diphosphogly- 
cerate is shown in Fig. I at three concentrations of ATP and two concentrations of 
Mg 2+. Increasing 2,3-diphosphoglycerate concentrations causes an increasing inhibition 
of hexokinase, but the curves become relatively fiat at 2,3-diphosphoglycerate concen- 
trations higher than about 2 5. IO ~ M 2,3-diphosphoglycerate. Inhibition by 2,3-di- 
phosphoglycerate is increased as the concentrations of ATP and/or Mg 2+ are decreased 
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zyme activity also decreases. The absolute activity in the control cuvettes (no 2,3-di- 
phosphoglycerate present) under the varying conditions illustrated in Fig. I are shown 
in Table I, under Expts. 1- 3. At the lowest concentrations of ATP and Mg 2+, hexo- 
kinase activity falls to only 15-2o % of its activity at more optimal concentrations 
of ATP and Mg 2+. 
T A B L E  I 
ABSOLUTE ACTIVITY OF ERYTHROCYTE HEXOKINASE UNDER VARYING CONDITIONS IN THE ABSENCE 
OF 2, 3-DIPHOSPHOGLYCERATE 
T h e  t a b l e  is k e y e d  t o  F i g s .  i -  3 b y  E x p t .  No .  D a t a  a r e  m e a n s  of  t h e  n u m b e r  of  a s s a y s  s h o w n  in  
p a r e n t h e s e s .  
Expt .  A T P  conch. M g  ~+ conch. A bs. activity 
No.  ;4 lO 4 (M) × I o  4 (M) (change in 
absorbance *) 
(6o mid  at23 c) 
i I.O i . o  0 . 0 2 4  (4) 
2 3.3 I.O 0 . 0 5 9  (IO) 
3 lO.O i o . o  o . 1 2 9  (5) 
4 67 i . o  O.Ol 7 
6. 7 I.O o .o61  
3.3 i . o  o .o61  
1.35 i . o  0 . 0 2 9  
0 .67  I .o o .o21 
5 - 7  67 .0  i o . o  o .o91  (5) 
6. 7 IO.O o .142  (5) 
3.3 IO.O 0 . 0 9 7  (5) 
1.35 lO.O o .o41  (5) 
0 .67  i o . o  0 -024  (5) 
8, 9 3.3 i o o . o  o .o91  (3) 
3-3 20 .0  0 . 0 7 6  (3) 
3.3 i o . o  o .o81 (3) 
3.3 5 .0 0 . 0 7 8  (3) 
3.3 2 .0  0 . 0 5 0  (3) 
3.3 i . o  ° . ° 5 1  (3) 
IO IO.O IOO.O O . 1 6 5  (2) 
IO.O 2 0 . 0  O . I 7 0  (2) 
IO,O IO.O o . 1 2 4  (2) 
IO.O 5.0  o. I I  7 (2) 
lO.O 2.0  0 . 0 5 4  (2) 
lO.O I.O 0 . 0 4 4  (2) 
* M e a s u r e d  w i t h  a i - c m  l i g h t  p a t h  in  a B e c k m a n  D U  s p e c t r o p h o t o m e t e r ,  w i t h  a h e m o g l o b i n  
c o n c e n t r a t i o n  in  t h e  c u v e t t e  of  o .17  g / i o o  ml .  
The family of curves obtained when ATP concentration is varied at three 
concentrations of 2,3-diphosphoglycerate and two of Mg 2+ is shown in Fig. 2. This 
figure illustrates the dramatic effect of 2,3-diphosphoglycerate inhibition of hexokinase 
activity as the molarity of ATP falls below 2. IO 4. Once again, the absolute amounts 
of hexokinase activity in the control cuvettes are shown in Table I under Expts. 4-7. 
Similar studies with Mg 2+ concentrations as the variable are shown in Fig. 3 
at two concentrations of 2,3-diphosphoglycerate and two of ATP. A marked inhibition 
of hexokinase by 2,3-diphosphoglycerate becomes apparent at low concentrations 
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of Mg 2+, particularly below 5"IO-1 M. Table I illustrates the absolute amounts of 
activity in the control cuvettes (Expts. 8 Io). 
80 \ 80 
0 7 0  ~ Ill'If ~ 7 0  
¢~ e . .  % Exper.men, >- 
60 ~', "x "'"'-.. 4 4 6O 
4 ~, DOG 45,t0-4M ~+ ---~ . . . .  ~ 4 0  8 
I " "~ '~ \ 6 ~M(~ IOxl0- M .. ~3 
o 3o|  ~._____~7 - £ - - - ~ -  --;2: ....... g 3c , >~T~ ~.3.0-~M 
0 ' I  / 4 , ~  . . . . . . .  - - - ~ :  . . . . . .  ~ I ~  ~ 9 , /DDG 30x10 4 M 
, aTp IOxlO 4M 
l-- I~ys,:.~ic ol ~o.ge ol ATP M 
I I I I I ' l  i I I I I 
2 4 6 8 I0 14 16' 60  I0 20 30 40  50 60  70 80  90  I00 
MOLARITY OF ATP x 104 MOLARITY OF Mg2*:~ IO 4 
Fig. ". F a m i l y  of c u r v e s  s h o w i n g  2 , 3 - d i p h o s p h o g l y c e r a t c  ( I )P( ; )  i n h i b i t i o n  of h e x o k i n a s e  as a 
f u n c t i o n  of .%]:[) c o n c e n t r a t i o n  a t  t h r e e  c o n c e n t r a t i o n s  of z,3 d i p h o s p h o g l y c e r a t e  a n d  t w o  of Mg ~ , 
Fig. 3. F a m i l y  of c u r v e s  s h o w i n g  , , 3 - d i p h o s p h o g l y c e r a t e  ( I )PG)  i n h i b i t i o n  of h e x o k i n a s e  as  a 
f u n c t i o n  of Mg "~ c o n c e n t r a t i o n  a t  t w o  c o n c e n t r a t i o n s  of A T P  and  t w o  of - ' , 3 - d i p h o s p h o g l y c e r a t c .  
DISCUSSION 
It seems likely that tile glycolytic rate of the red (:ell can under some circum- 
stances be limited by hexokinase activity. The maximal hexokinase activity of hem(> 
lysates is lower than that of any other enzyme of glycolysis 12. In studies of enzyme 
activities v e r s u s  glycolytic rates in a series of intact red cells of mammalian organisms, 
an amazingly good correlation with hexokinase activity was found, considerably 
better than with other glycolytic enzymes ~a. Hexokinase activity as measured in 
hemolvsates is 3 5 times greater than in intact cells m, 1~, indicating that hexokinase 
is in an inhibited state in intact cells. The level of 2,3-diphosphoglycerate is sufficiently 
high in erythrocytes to make it a likely candidate for this inhibition. With sufftcienth, 
low levels of either ATP or Mg 2+ through binding or other mechanisins, hexokinase 
inhibition by -%3-diphosphoglycerate would become a factor even if it were not other- 
wise. 
In the fully oxygenated cell as it comes from the lung, less of the 2,3-diphospho- 
glycerate and ATP would be bound by hemoglobin than in the tissues ~4. As the erythro- 
cvte passes through the tissues, the resulting desaturation will result in increased 
l)inding of 2,3-diphosphoglycerate by hemoglobin ~4, possibly decreasing inhibition of 
hexokinase, depending upon ATP and Mg 2+ concentration and on the amount of total 
2,3_diphosphoglycerate in that particular individual's erythrocytes. The amount of 
ATP available to hexokinase is critical to its activity (Table I) and critical to the 
amount of inhibition by 2,3-diphosphoglycerate (Fig. 2). Some proportion of the ATP 
molecules will presumably be bound to deoxyhemoglobin as the cell loses oxygen in 
the tissues, and, in addition some ATP will be bound to various enzymes. A question 
of considerable importance, then, is the relative binding of ATP v e r s u s  2,3-di- 
phosphoglycerate to hemoglobin. 
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Similar considerations hold for Mg 2+. At low concentrations of free Mg 2+ in- 
hibition of hexokinase by 2,3-diphosphoglycerate is severe (Fig. 3). As the concen- 
tration of Mg 2+ is increased the inhibition of hexokinase by 2,3-diphosphoglycerate is 
relieved even at fairly low ATP concentrations. The physiological range of total Mg 2+ 
within the red cell is shown in Fig. 3- However, current evidence indicates only about 
5 % of the Mg 2+ in the red cell is unbound 15-17, placing the free Mg 2÷ level on the steep 
portion of the 2,3-diphosphoglycerate-hexokinase inhibition curve, and suggesting 
Mg 2+ as a possible important regulator of red cell metabolism. 
The probable explanation for the failure of DEVERDIER AND GARBY 1° to find 
2,3-diphosphoglycerate inhibition of hexokinase may involve the use of high concen- 
trations of Mg 2+, and to a lesser extent ATP, in their incubations. As shown here, 
2,3-diphosphoglycerate inhibition of hexokinase is profoundly relieved by increasing 
concentrations of these two substances. 
I t  seems clear that the mammalian red cell is organized in a complex manner in 
order to perform its vital function of gas transport. It  is becoming apparent that the 
metabolism of the cell is intimately involved with hemoglobin function. 2,3-Diphos- 
phoglycerate and ATP seem to be vital links in this respect, both in modifying the 
oxygen affinity of hemoglobin and in affecting glycolysis. Inhibition of hexokinase 
by 2,3-diphosphoglycerate with modulation by ATP and/or Mg *+, seems ideally suited 
for feedback control of glycolysis and hence of the level of 2,3-diphosphoglycerate 
and ATP, which in turn regulate hemoglobin function. 
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